<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633007</url>
  </required_header>
  <id_info>
    <org_study_id>CVT-301-008</org_study_id>
    <nct_id>NCT02633007</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma</brief_title>
  <official_title>A Phase 1 Study of the Safety and Pharmacokinetics (PK) of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acorda Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acorda Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, randomized, placebo-controlled, 2-period, crossover study to
      evaluate safety and PK of 3 doses of CVT 301 levodopa (l-dopa) in adults with asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulmonary function</measure>
    <time_frame>within 90 min prior to dose administration and specified time points up to 24 hours after first inhalation</time_frame>
    <description>Pulmonary function will be measured by spirometry using the guideline specified by the Third National Health and Nutrition Examination Survey (NHANES III)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with Adverse Events (AEs) including Serious AEs</measure>
    <time_frame>up to 12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma drug concentration (Cmax)</measure>
    <time_frame>within 30 min prior to first CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed plasma drug concentration (Tmax)</measure>
    <time_frame>within 30 min prior to first CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve over the dosing interval (AUC0-last)</measure>
    <time_frame>within 30 min prior to first CVT-301 dose administration and specified time points up to 24 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CVT-301 then Placebo (AB)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo then CVT-301 (BA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive both CVT-301 and placebo in two dosing periods separated by one day. Subjects will be randomized 1:1 into sequence AB or BA [CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)] and they will start pre-treatment of carbidopa (as Lodosyn®) administered every 8 hours until the completion of all study treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CVT-301 (levodopa inhalation powder)</intervention_name>
    <description>Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.</description>
    <arm_group_label>CVT-301 then Placebo (AB)</arm_group_label>
    <arm_group_label>Placebo then CVT-301 (BA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbidopa</intervention_name>
    <description>Administered orally according to the carbidopa dosing schedule.</description>
    <arm_group_label>CVT-301 then Placebo (AB)</arm_group_label>
    <arm_group_label>Placebo then CVT-301 (BA)</arm_group_label>
    <other_name>Lodosyn ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.</description>
    <arm_group_label>CVT-301 then Placebo (AB)</arm_group_label>
    <arm_group_label>Placebo then CVT-301 (BA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects will be men or women in good general health with a diagnosis of mild
             or moderate asthma;

          -  On a stable regimen of asthma medications for at least 30 days prior to screening;

          -  Body mass index (BMI) 18 to 32 kg/m2;

          -  Forced expiratory volume in one second (FEV1) ≥60% of predicted for race, age, sex,
             and height;

          -  FEV1/FVC (forced vital capacity) ratio ≥70%.

        Exclusion Criteria:

          -  More than 2 hospitalizations or emergency room visits, or more than 3 courses of
             systemic steroids in the past 12 months or 1 course within the past 8 weeks for
             respiratory illness;

          -  Asthma exacerbation within 8 weeks before screening;

          -  Unscheduled or urgent visit to any medical facility for asthma-related problems within
             8 weeks before screening;

          -  History of intubation or intensive care unit admission for asthma in the past 5 years;

          -  History of chronic obstructive pulmonary disorder (COPD) requiring intermittent or
             continuous use of any oral or inhaled medication therapy within last 3 years;

          -  Renal impairment as defined by a calculated creatinine clearance of ≤ 80 mL/minute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Murck, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Acorda Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 002</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 001</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 003</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2015</study_first_submitted>
  <study_first_submitted_qc>December 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

